|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0003241,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0035015,
umls-concept:C0079189,
umls-concept:C0871261,
umls-concept:C1167395,
umls-concept:C1509147,
umls-concept:C1515655,
umls-concept:C1548437,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882923,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-3-9
|
|
pubmed:abstractText |
Activated macrophages are the major producers of heterodimeric cytokine interleukin-12 (IL-12). Earlier evidence suggested that early rejection of AK-5 tumours is mediated by IL-12 through interferon-gamma (IFN-gamma) production, involving activation of natural killer (NK) cells and upregulation of T-helper 1 (Th1)-type cytokine response. Injection of anti-IL-12 antibody into AK-5 tumour-bearing animals resulted in a large number of changes in the host immune response towards the tumour. These animals showed diminished NK-mediated antibody-dependent cell-mediated cellular cytotoxicity (ADCC) activity, down-regulation of Th1-type cytokine response, decreased anti-tumour antibody response ultimately leading to either delay or inhibition of the tumour-regression process. There was also increased production of IL-10 in the animals that had received anti-IL-12 antibody thereby resulting in the down-regulation of IL-2 and IFN-gamma production. IL-12 plays a major role in the activation of the different immune parameters responsible for early rejection of AK-5 tumour. We also studied the activation status of macrophages from tumour-transplanted animals and their ability to produce IL-12. Monocytes/macrophages from antibody-injected animals were less active and produced lower quantities of IL-12, IL-1 beta and tumour necrosis factor-alpha (TNF-alpha) as compared with the macrophages from AK-5 tumour-bearing animals.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1319280,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1346796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1346797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1352483,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1357073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1673147,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1674604,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-1940799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2145365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2419430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2496168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2504877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2582266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-2960769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-3457975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7527811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7553237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7585539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7743551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7836910,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7843218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7908232,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7908322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7913943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-7994020,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8102154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8102388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8103338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8104230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8551218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8557984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8640858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-8796899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9486112-9384688
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0019-2805
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
381-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9486112-Animals,
pubmed-meshheading:9486112-Cytokines,
pubmed-meshheading:9486112-Cytotoxicity, Immunologic,
pubmed-meshheading:9486112-Histiocytoma, Benign Fibrous,
pubmed-meshheading:9486112-Immune Tolerance,
pubmed-meshheading:9486112-Interleukin-12,
pubmed-meshheading:9486112-Killer Cells, Natural,
pubmed-meshheading:9486112-Macrophage Activation,
pubmed-meshheading:9486112-Neoplasm Transplantation,
pubmed-meshheading:9486112-Rats,
pubmed-meshheading:9486112-Rats, Wistar,
pubmed-meshheading:9486112-Skin Neoplasms
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Administration of anti-IL-12 antibody in vivo inhibits rejection of a rat histiocytoma and suppresses cytokine response in a tumour-bearing host.
|
|
pubmed:affiliation |
Centre for Cellular and Molecular Biology, Hyderabad, India.
|
|
pubmed:publicationType |
Journal Article
|
